September 2021

Press Release: Francis Medical Announces Close of $55 Million Series B Equity Financing

2021-09-15T02:31:36+00:00September 15th, 2021|In the Press|

September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.

June 2021

Press Release: Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer

2021-06-08T17:46:06+00:00June 8th, 2021|In the Press|

June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments.

March 2021

October 2020

September 2020

August 2020

June 2020

Press Release: Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer

2021-02-04T18:14:08+00:00June 9th, 2020|In the Press|

June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer.

April 2020

October 2019

December 2018

Press Release: Francis Medical Launches with $18M Series A Funding

2021-02-04T20:52:02+00:00December 13th, 2018|In the Press|

December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy.